Results: 4

1.
Fig. 3

Fig. 3. From: Oral Bisphosphonates and Risk of Subtrochanteric or Diaphyseal Femur Fractures in a Population-Based Cohort.

Kaplan-Meier curves for fracture-free survival in oral bisphosphonates versus raloxifene/calcitonin nasal spray.

Seo Young Kim, et al. J Bone Miner Res. 2011 May;26(5):993-1001.
2.
Fig. 4

Fig. 4. From: Oral Bisphosphonates and Risk of Subtrochanteric or Diaphyseal Femur Fractures in a Population-Based Cohort.

Hazard ratios (HRs) for subtrochanteric or diaphyseal femur fractures according to osteoporosis treatment duration.

Seo Young Kim, et al. J Bone Miner Res. 2011 May;26(5):993-1001.
3.
Fig. 2

Fig. 2. From: Oral Bisphosphonates and Risk of Subtrochanteric or Diaphyseal Femur Fractures in a Population-Based Cohort.

Flow diagram of cohort selection. PACE = Pennsylvania Pharmaceutical Assistance Contract for the Elderly; PAAD = New Jersey Pharmaceutical Assistance to the Aged and Disabled.

Seo Young Kim, et al. J Bone Miner Res. 2011 May;26(5):993-1001.
4.
Fig. 1

Fig. 1. From: Oral Bisphosphonates and Risk of Subtrochanteric or Diaphyseal Femur Fractures in a Population-Based Cohort.

Study design. Subjects were required to have at least one claim each during the prior three 6-month intervals. For both the primary (“as treated”) and secondary (“first exposure carried forward”) analyses, follow-up began on the 91st day after filling the first prescription of either exposure of interest. The second prescription fill for the same exposure drug group was required during the 90-day lag period. For the primary analysis (A), we continued the follow-up until 90 days after the last drug available date. Last drug available date was calculated with a number of days of supply after the last prescription fill date. For the secondary analysis (B), the follow-up continued until 365 days after the index date. Patients were considered “always exposed” for the first exposure drug group during the follow-up period. In a sensitivity analysis (C), follow-up began at the first prescription fill and ended 90 days after the last drug available date.

Seo Young Kim, et al. J Bone Miner Res. 2011 May;26(5):993-1001.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk